Sector News

Centessa’s new chief medical officer has AstraZeneca’s Tagrisso, Lynparza on his resume

May 16, 2021
Life sciences

The resume of Antoine Yver, M.D., includes several of AstraZeneca’s most well-known approved cancer drugs and who’s who of Big Pharma. He will now bring that expertise to Centessa Pharmaceuticals as its new chief medical officer.

Yver leaves behind a legacy of moving 11 different medicines through development to approval for AstraZeneca, which also include the Merck-partnered cancer drug Lynparza and Enhertu, the $6.9 billion partnered oncology med with Daiichi Sankyo, as well as working on its major lung cancer drug Tagrisso.

Centessa’s new executive most recently served at Daiichi Sankyo, where he was executive vice president and global head, R&D oncology, as well as chair of the Cancer Enterprise. Before that, he was AstraZeneca’s senior vice president, global medicine head, oncology, and global medicines development China lead. Yver also spent time at Merck, Johnson & Johnson and Aventis Pharmaceuticals, which is now a part of Sanofi.

“Antoine is a true industry leader with significant experience and success as a drug developer, having developed some of the most impactful oncology drugs in the world,” said Centessa CEO Saurabh Saha, M.D., Ph.D. “I look forward to partnering with him as we advance our portfolio of preclinical programs into the clinic and progress our four assets currently in clinical development.”

Yver will oversee a broader portfolio at Centessa, which focuses on overhauling the drug development process using an asset-centric R&D model. The Cambridge, Massachusetts-based company has over a dozen therapies in development, including the phase 3 clinical asset Lixivaptan in autosomal dominant polycystic kidney disease.

A number of products in Centessa’s portfolio are epidermal growth factor receptor inhibitors, which target a particular mutation common in non-small cell lung cancer and other malignancies.

“Centessa’s asset-centric model exemplifies the very best practices that I have experienced and implemented in the industry,” Yver said in a statement.

The company launched in February with a series A funding but quickly made the move to IPO. Centessa, which formed from the merger of 10 different biotechs, filed to raise $100 million and join the public markets in late April.

Yver’s appointment is the latest staff shuffle for the brand new biopharmaceutical company, which launched with Moncef Slaoui, M.D., as chief scientific officer. The Operation Warp Speed alum stepped down in March amid allegations of sexual assault at his former employer, GlaxoSmithKline.

by Annalee Armstrong

Source: fiercebiotech.com

comments closed

Related News

September 19, 2021

From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year

Life sciences

This year has already witnessed a handful of memorable FDA approvals. But the race isn’t over yet. Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Those meds combined are worth roughly $7.1 billion in sales cumulatively by 2026, according to Evaluate’s estimates.

September 19, 2021

Horizon partners with MIT for crowdsourced rare disease solutions, narrows to 5 finalists

Life sciences

Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point. For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.

September 19, 2021

Research identifies possible link between antibiotic use and breast cancer growth

Life sciences

Researchers from the Quadram Institute and the University of East Anglia (UEA) discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew.

Send this to a friend